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ABSTRACT
Objective: Short-chain fatty acids (SCFAs) are produced by the gut microbiota and may reflect health. Gut symptoms are common in in-
dividuals with depressive disorders, and recent data indicate relationships between gut microbiota and psychiatric health. We aimed to in-
vestigate potential associations between SCFAs and self-reported depressive and gut symptoms in young adults.
Methods: Fecal samples from 164 individuals (125 were patients with psychiatric disorders: mean [standard deviation]
age = 21.9 [2.6] years, 14% men; 39 nonpsychiatric controls: age = 28.5 [9.5] years, 38% men) were analyzed for the SCFA acetate, bu-
tyrate, and propionate by nuclear magnetic resonance spectroscopy. We then compared SCFA ratios with dimensional measures of
self-reported depressive and gut symptoms.
Results:Depressive symptoms showed a positive association with acetate levels (ρ = 0.235, p = .003) and negative associations with both
butyrate (ρ = −0.195, p = .014) and propionate levels (ρ = −0.201, p = .009) in relation to total SCFA levels. Furthermore, symptoms of
diarrhea showed positive associations with acetate (ρ = 0.217, p = .010) and negative associations with propionate in relation to total SCFA
levels (ρ = 0.229, p = 0–007). Cluster analysis revealed a heterogeneous pattern where shifts in SCFA ratios were observed in individuals
with elevated levels of depressive symptoms, elevated levels of gut symptoms, or both.
Conclusions: Shifts in SCFAs are associated with both depressive symptoms and gut symptoms in young adults and may have of rele-
vance for treatment.
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INTRODUCTION
The World Health Organization lists major depressive disorder(MDD) as a leading cause of disability in the world, and it is
currently associated with an annual suicide rate of approximately
800,000 individuals (1). Furthermore, MDD and related disorders
affect about 300 million people worldwide (2). However,
knowledge of the underlying pathophysiology is lacking, resulting
in poor treatment and outcome for many patients (3).
It is clear that several neurotransmitter systems, including sero-
tonergic, dopaminergic, and glutamatergic systems, may have al-
tered function in MDD. Postprandial serotonin levels in plasma
are altered in irritable bowel syndrome (IBS) compared with con-
trols; elevated serotonin was found when diarrhea predominant
and low when constipation is predominant (4). Young adult
patients seeking psychiatric care reported more gastrointestinal
(GI) symptoms than controls and the level of GI symptoms were
associated with depressive symptom severity and trait anxiety
(5). We have also shown links between IBS symptoms and
circulating levels of melatonin as well as symptoms of anxiety
and depression (5–7). The intestinal microbiota influences both
neural, endocrine signaling and local and systemic immune
responses. For example, many of the common neurotransmitters
in our nervous system and GI tract can also be synthesized by
commensal bacteria (8). Furthermore, hypothalamic-pituitary-
adrenal axis abnormalities have been identified in individuals
with depression (9). Previous studies have shown the potential
influence of the gut microbiota and its effects on central
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regulatory systems that may influence body and brain function
(10) including the hypothalamic-pituitary-adrenal axis (11).
Corticotropin-releasing hormone administration results in higher
ACTH in patients with IBS compared with controls and genetic
variations in a CRH receptor gene have been linked to high
anxiety trait and an increased risk of developing stress-induced
psychopathology (12,13). Another proposed mechanism via
CRH is mast cell activation and the release of proteases (14).
Altered gut microbiotia composition, increased gut permeability,
changes in enteroendocrine activity, and dysregulation of the
immune system all interact and influence brain function (15,16).
Short-chain fatty acids (SCFAs) are bacterial fermentation
products that have the potential to influence the intestinal immune
responses (17). In the gut, the most abundant SCFAs are acetate,
propionate, and butyrate in a molar ratio of 3:1:1 accounting for
>95% of the SCFA content (18). Acetate, propionate, and
butyrate have multiple functions including energy supply,
stimulation of epithelial cell proliferation, and activation of G
protein–coupled cell surface receptors, as well as direct effects
on substrate and energy metabolism in peripheral tissues such as
the liver and skeletal muscles (18). SCFAs can also stimulate gut
endocrine cells to increase serotonin production (19).
A new field of research indicates that bacterial products including
SCFAsmay also play amajor role in stress-induced disorders including
anxiety- and depressive-like behavior. A recent rodent study showed
that SCFAsupplementation could counter the effects of chronic psycho-
social stress on anxiety- and depressive-like symptoms and behavior
(20). However, most of the studies investigating the role of SCFAs
and their potential beneficial functions on brain and behavior are
based on rodent models increasing the need of human studies on this
topic. There are numerous reports linking IBS with depressive/anxiety
disorders (21,22). Because microbial dysbiosis has been implicated as
causative to gut-related symptoms in IBS, it is possible that shifts in
SCFAs will be associated with both depressive symptoms and IBS.
The aim of the present study was to test if the levels of acetate,
propionate, and butyrate in feces are related to self-reported symp-




Participants in this study were patients recruited to participate in “Uppsala
Psychiatric Patient Samples,” a project for collection of biological material
from patients seeking psychiatric care at the Department of General Psychi-
atry at Uppsala University Hospital, Sweden. The patients in this study
were recruited to Uppsala Psychiatric Patient Samples between
September 2012 and February 2015. During this period, 388 patients were
recruited to the biobank (23), and fecal samples from these 125 patients
were available for SCFA analysis. Moreover, samples from 39 control
individuals were available for SCFA analysis. The controls included staff
members of the Uppsala University Hospital and students from Uppsala
University. Assessment of psychiatric diagnoses was performed by
trained personnel using the Swedish version of the Mini-International
Neuropsychiatric Interview.
Ethical Approval
The study was approved by the Regional Ethics Committee in Uppsala
(2012/081 and 2013/219). All participants signed an informed consent form.
Depressive Symptoms (Montgomery-Åsberg
Depression Rating Scale—Self-Assessment)
The self-rating version of the Montgomery-Åsberg Depression Rating
Scale—Self-Assessment (MADRS-S) was used for rating depressive
symptoms (24–27). The MADRS-S has been demonstrated to be a
reliable patient-administered tool for depressive symptoms and consists
of nine questions rated on a 0 to 6 Likert scale, with a possible score
range from 0 to 54 (28).
Gastrointestinal Symptoms
We used the Swedish translation of the Gastrointestinal Symptom Rating
Scale for IBS (GSRS-IBS) to evaluate GI symptoms. This is a validated
self-assessment instrument for evaluating IBS symptoms that is able to dis-
criminate symptom severity and frequency (29). The participants (both
patients and controls) reported GI symptoms during the last week and
scored the symptoms from 1 to 7 using the Likert scale, with possible
total scores ranging from 13 to 91 points. The questionnaire includes 13
questions that are grouped into symptom clusters: pain syndrome,
bloating syndrome, constipation syndrome, diarrhea syndrome, and satiety.
Analysis of SCFAs
SCFA has been analyzed using nuclear magnetic resonance (NMR) spec-
troscopy. Between 100 and 500 mg of stool sample was diluted with
1.5 mL sodium phosphate buffer (0.4 M, pH 7.0), homogenized by vortex
mixing and centrifuged at 6300 rpm at 4°C for 15 minutes. From the super-
natant, 1.5 mL of fecal water has been transferred to a fresh tube and sub-
jected to centrifugation at 20,000g at 4°C for 15 minutes. This step was
repeated once with 1 mL of supernatant recovered from the previous centri-
fugation. Finally, 525 μL of the supernatant was mixed with 45 μL D2O
and 30 μL internal standard. Each sample solution (560 μL) was trans-
ferred to a 5-mmNMR tube, and the 1H NMR spectra were acquired using
a Bruker Advance III spectrometer operating at 600-MHz proton frequency
and equipped with a cryogenically cooled probe and an autosampler. Each
spectrum was recorded (25°C, 128 transients, acquisition time of 1.8 sec-
onds, relaxation delay of 4 seconds) using a zgesgp pulse sequence (Bruker
Biospin) using excitation sculpting with gradients for suppression of the
water resonance. For each spectrum, 65,536 data points were collected over
a spectral width of 17,942 Hz (30). All NMR spectra were processed using
Bruker TopSpin 4.1 software. The data were Fourier transformed after
multiplication by a line broadening of 0.3 Hz and referenced to internal
standard peak TSP at 0.0 ppm. Baseline and phase were corrected
manually. Each spectrum was integrated using Amix 3.7.3 (Bruker
BioSpin GmbH, Rheinstetten, Germany) into 0.01-ppm integral regions
between 0.41 and 10 ppm, in which areas between 4.52 and 5.00 ppm
were excluded. Each integral region was referenced to the internal
standard. The integral regions corresponding to SCFAs were adjusted for
milligrams of stool samples extracted and used for further statistical
analysis. Few samples were analyzed with lesser sample amounts.
Absolute numbers and calculation can be found in the Supplemental
Digital Content file, http://links.lww.com/PSYMED/A756. Relative ratios
of SCFAs were used for statistical analysis, as these were less dependent
on time or temperature differences during sample handling (31).
Statistical Analysis
Before all analyses, the variables were screened for the distribution of nor-
mality with Shapiro-Wilk test of normality (p > .05) and visually estimated
for normal distribution (histogram, Q-Q-plot box-plot). We calculated ace-
tate, butyrate, and propionate reference values as a ratio each to the total
SCFAs (sum of acetate, butyrate, and propionate) in the sample. We per-
formedMann-Whitney tests to investigate the statistical difference between
patient and controls regarding ratios of acetate, butyrate, and propionate;
sex; and psychiatric medication. Bivariate analysis was performed to test
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if body mass index (BMI) and age were associated with SCFAs with Spear-
man rank correlation.
Correlation analysis (partial Spearman rank-order correlations) was
performed to analyze if acetate, butyrate, and propionate ratios were related
to depressive symptoms severity (MADRS-S total score) and self-reported
GI symptoms (GSRS-IBS). In all partial correlations analyses, we con-
trolled for BMI and use of psychiatric medication (yes/no). Individuals with
incomplete or missing symptomatic data were also excluded from the re-
spective statistical analyses (missing data for MADRS-S [n = 2],
GSRS-IBS [n = 20], and BMI [n = 5]). The significance level was set to
a p value less than .05, and because we considered our study as an extensive
pilot study, with low statistical power, we did not perform any corrections
for multiple testing. We did dimensional analyses and combined cases
and controls because controls were also displaying a range of both depres-
sive and gut-related symptoms.
A hierarchical linear regression model was performed with MADRS-S
total score as the dependent variable. Predictors included in the first
model were SCFA ratios, BMI, age, and psychiatric medication (yes/
no), and then the GI symptoms were added in the second model and
the change in R2 was noted. These statistical analyses were conducted
using the SPSS Statistics Version 25.
Cluster analysis was performed using the statistical software R. A heat
map was created to visualize the relationship between the individual gut
and depressive symptoms and the SCFA ratios (using the package
ggplots2). For the cluster analysis, only 137 individuals had complete data
from GSRS-IBS, MADRS-S, and SCFA ratios, which were respectively
transformed to z scores. To visualize the distribution of data, high levels
or scores are coded orange, whereas low levels or scores are coded purple.
The BMI on the left side of the heat map is colored blue, where low BMI is
colored light blue. To illustrate patients and controls, on the right-side
TABLE 1. Relevant Characteristics of the Cohort
Patients (n = 125) Controls (n = 39)
Age, mean (SD), y 21.9 (2.6) 28.5 (9.5)
Sex, men/women (% men) 17/108 (14) 15/24 (38)
BMI, median (range), kg/m2 22.4 (15.1–46.6) 23.0 (18.1–37.8)
MADRS-S total score, median (range) 22 (0–49) 5 (0–20)
GSRS-IBS total score, median (range) 31.5 (13–78) 23.0 (13–47)
Medication, n (%)
Any medication 106 (84.8) 20 (51.2)
Any psychiatric medication 82 (66) 3 (8)
Other anxiolytic medicationa 29 (23) 0 (0)
Antidepressive treatmentb 58 (46) 3 (7.7)
Antipsychotics 7 (5.6) 0 (0)
Antiepileptics 11 (8.8) 0 (0)
Benzodiazepines 4 (3.2) 0 (0)
Z analogs 7 (5.6) 0 (0)
Immune modulating 8 (6.4) 0 (0)
Diagnosis, n (%)
Current depressive episode (UP/BP) 68 (54.4) 0 (0)
Any bipolar disorderc 23 (18.4) 0 (0)
Celiac disease 1 (0.8) 0 (0)
Systemic inflammatory diseased 4 (3.2) 0 (0)
Lifetime depressive episode (UP) 73 (58.4) 5 (13.8)
Any anxiety disorder, DSM-IV 85 (68) 1 (2.5)
Anorexia 0 (0) 0 (0)
Bulimia nervosa 10 (8) 0 (0)
SCFAs
Acetate ratio, median (range) 0.77 (0.45–0.98) 0.76 (0.44–0.87)
Butyrate ratio, median (range) 0.05 (0.01–0.12) 0.05 (0.03–0.09
Propionate ratio, median (range) 0.18 (0.01–0.43) 0.18 (0.08–0.51)
SD = standard deviation; BMI = bodymass index (missing data for 4 patients); MADRS-S =Montgomery-Åsberg Depression Rating Scale—Self-Assessment (missing data for 1
patient); GSRS-IBS = Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (missing data for 14 patients and 4 controls); UP/BP = unipolar/bipolar disorder;
DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; SCFAs = short-chain fatty acids.
a Sedating antihistamines, phenothiazines.
b Selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitor, mood stabilizers, and atypical antidepressants.
c Bipolar types I and II and nonspecified.
d Systemic inflammatory disease, that is, four cases of inflammatory bowel disorder.
One patient had comorbid high functioning autism and dyslexia, one patient had comorbid attention-deficit/hyperactivity disorder, one case presented psychotic symptoms, and one
patient has since this study started committed suicide.
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values that represent patients are in black and controls aremarked gray. Fur-
thermore, to visualize the clusters better, we colored the columns showing
MADRS-S items in pink, the SCFA ratios in green, and the GSRS-IBS
items in turquoise.
RESULTS
The sample’s characteristics are described in Table 1. In the bivar-
iate analyses, acetate ratios were negatively associated with BMI
(−0.156, p = .049), but no associations were found to butyrate ra-
tios (0.103, p = .196) or propionate ratios (0.132, p = .097). No re-
lationship to SCFA ratios was found between age and sex. Patients
did not differ as a group from controls regarding acetate, butyrate,
and propionate ratios (Table S1, Supplemental Digital Content,
http://links.lww.com/PSYMED/A756). However, we could see a
tendency toward an association between acetate and butyrate ratios
and psychiatric medication and use of antidepressants (Table S1).
Based on these findings, the partial correlations below were ad-
justed for BMI and psychiatric medication (Y/N).
Depressive symptoms severity (total MADRS-S score) was
correlated with acetate ratio (ρ = 0.235, p = .003), butyrate ratio
(ρ = −0.195, p = .014), and propionate ratio (ρ = −0.207,
p = .009) when adjusting for BMI and psychiatric medication. Re-
analysis of the patient data alone gave similar results (Table 2).
BMI, butyrate and propionate ratios, age, and medication were
the included predictors in a linear regression model with
MADRS-S as the dependent factor (R2 = 0.307, p = 1.3726E − 9).
Exploratory analyses to investigate the associations with the
separate MADRS-S items (nine questions) and the three SCFA ra-
tios were performed in a post hoc analysis (shown in Table 2). Pos-
itive associations were found between acetate ratio and five of the
MADRS-S items (mood, feelings of unease, initiative, emotional
involvement, and pessimism), but no significant associations were
found for sleep, ability to concentrate, appetite, and zest for life.
Butyrate and propionate showed an inverse pattern of associations
with the same items as acetate (Table S2, Supplemental Digital
Content, http://links.lww.com/PSYMED/A756).
The subsequent exploratory analysis of correlations between
SCFA ratios and diverse GI symptom items (GSRS-IBS) is shown
in Table 3. A positive association was found between acetate ratios
and the GSRS-IBS items diarrhea and bloating, whereas negative
associations were found between constipation and butyrate ratios
and diarrhea and propionate ratios (Table 3.) These findings
were not affected by adjustment factors of BMI and psychiatric
medications (data not shown). The total scores for of MADRS-S
and GSRS-IBS were correlated (ρ = 0.320. p = .0001). To test
what percentage of variance of the MADRS-S–SCFA association is
“accounted for” by GI symptoms, a hierarchical linear regression
model showed that adding GI symptoms to the aforementioned
original model increased the explained variance with nearly 6%
(change in R2 = 0.065, p = .052). Excluding patients with
bulimia nervosa from the analysis did not change the results.
To visualize the relationships between the symptoms and SCFA
ratios, we performed cluster analyses. As shown in Figure 1, a heat
map illustrates the clusters of the separate items of MADRS-S and
GSRS-IBS, as well as the acetate, butyrate, and propionate ratios
(Figure 1). Six clusters are highlighted in the heat map, illustrated
as black rectangles around the respective grouping. Cluster I con-
tains patients with mixed depressive symptoms and GI symptoms
with predominance of diarrhea and lower propionate ratios. Cluster
II includes patients with high depressive scores and lower scores on
other gut symptoms and shows lower butyrate and propionate ratios.
Cluster III describes a third group of individuals with both low gut
and depressive symptoms. Interestingly, this small group has very
low acetate ratios and higher butyrate and propionate ratios. Cluster
IV includes patients with both depressive symptoms and gut-related
issues with predominance of pain and obstipation and lower buty-
rate ratios. Cluster V includes controls and patients with some GI
symptoms and elevated acetate ratios. Cluster VI, in the lowest rect-
angle, controls with low depressive scores but with some GI symp-
toms also seem to have lower acetate and propionate ratios and
somewhat higher butyrate ratios.
DISCUSSION
This pilot study found relationships between depressive and GI
symptoms and the ratios of three major SCFAs measured in fecal
TABLE 2. Relation of Depressive Symptoms and Acetate, Butyrate, and Propionate Ratios, Shown by Correlation Coefficients and
Two-Tailed p Values for Partial Bivariate Associations Between the SCFA Ratios and the Montgomery-Åsberg Depression Rating
Scale—Self-Assessment
Population Acetate Butyrate Propionate
MADRS-S P and C 0.235 (0.003) −0.195 (0.014) −0.207 (0.009)
MADRS-S P 0.231 (0.012) −0.246 (0.007) −0.181 (0.050)
Adjusted for body mass index, age, and use of psychiatric medications (Y/N). Bold values indicate an association with a p value of less than .05. Reanalysis of the patient (P) data
excluding controls (C) gave comparable results.
MADRS-S = Montgomery-Åsberg Depression Rating Scale—Self-Assessment; SCFA = short-chain fatty acid.
TABLE 3. Post Hoc Analysis of Acetate, Butyrate, and
Propionate Ratios in Relation to Gastrointestinal Symptoms
Measured Using the Gastrointestinal Symptom Rating Scale
for IBS (GSRS-IBS)
GSRS-IBS Symptoms Acetate Butyrate Propionate
Satiety 0.076 (n.s.) −0.113 (n.s.) −0.053 (n.s.)
Diarrhea 0.217 (.010) −0.048 (n.s.) −0.229 (.007)
Constipation −0.031 (n.s.) −0.169 (.046) 0.082 (n.s.)
Bloating 0.172 (.043) −0.156 (n.s.) −0.148 (n.s.)
Pain 0.117 (n.s.) −0.120 (n.s.) −0.098 (n.s.)
Correlation coefficients and two-tailed p values in parentheses for associations
between short-chain fatty acid ratios and the separate GSRS-IBS items. n = 152.
Adjusted for body mass index, age, and use of psychiatric medications (Y/N). Bold
values indicate an association with a p value of less than .05.
IBS =irritable bowel syndrome; GSRS-IBS = GSRS-IBS = Gastrointestinal Symptom
Rating Scale for IBS.
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material from a mixed cohort of young adults with and without
psychiatric diagnoses. These associations were independent from
BMI and psychiatric medication. Furthermore, exploration of the
data revealed groups of individuals with depressive symptoms,
GI symptoms alone, or in combination may show shifts in SCFA
ratios with relevance for both patients and controls.
Our results indicate that shifts in SCFA ratios are associated
with both IBS and depression. We have previously explored the
correlation between GI and depressive symptoms in young adults
and shown high correlations (5). Our results indicate that the
associations between SCFAs and depressive symptoms are both
stronger than and independent from GI symptoms. A bidirectional
FIGURE 1. Heat map of the separateMADRS-S and GSRS-IBS items and acetate, butyrate, and propionate ratios. A heat map visualizing
the relationship between individual gut and depressive symptoms and SCFA ratios. For the cluster analysis, only 137 individuals had
complete data from GSRS-IBS, MADRS-S, and SCFA analysis. Orange boxes represent high levels/scores of the respective items, and
purple boxes represent low levels/scores of these items. BMI levels are indicated in blue, where light blue indicates low BMI (left
panel). To illustrate individual groups, patients are colored with black boxes and controls in gray boxes (right panel). The MADRS-S
items are in pink, SCFAs in green, and the GSRS-IBS items in turquoise (lower panel). MADRS-S = Montgomery-Åsberg Depression
Rating Scale—Self-Assessment; GSRS-IBS = Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome; SCFA =
short-chain fatty acid; BMI = body mass index. Color image is available online only at www.psychosomaticmedicine.org.
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interaction between gut symptoms and the brainmediated by the gut
microbiota and their respective metabolites has been proposed
(32–34). SCFAs in addition to local influences on epithelial cells
(35) activate G protein–coupled receptors (36) and are involved in
neurotransmitter production (37). Moreover, SCFAs can penetrate
the blood-brain barrier (38). Differences in the SCFA composition,
because of changes in microbiota, correlate with neural activity
and brain structure in humans, as assessed by functional and
structural magnetic resonance imaging (39).
Although studies examining SCFAs differ in their design by
measuring different populations, feces, or blood and calculating
absolute or relative levels, which makes comparison between stud-
ies more difficult, some findings are consistent. Our study showed
that acetate and butyrate are associated with depressive and GI
symptoms, but the relationships seem to go in opposite directions.
In agreement with earlier work, acetate was positively correlated
with BMI in our material. Elevated levels of acetate in feces have
been shown to be associated with obesity in several studies and
were recently summarized in a meta-analysis but do not reach sig-
nificance after corrections for cofactors in other studies on older
populations (40). The relationship between depressive and GI
symptoms was independent from BMI in this young adult
population, raising an interesting hypothesis that these symptoms
in combination with SCFA disruption may predispose for future
metabolic syndrome and obesity in later life. The negative
association between butyrate ratio and depressive GI symptoms
in this study was weak and is in line with earlier findings and
proposed positive impact of butyrate on health (41). These
findings raise questions as to the potential future therapies. Oral
administration of butyrate has been suggested to be beneficial for
a wide spectrum of diseases, ranging from metabolic diseases to
colorectal cancers (42). Fiber-rich diets such as the “Mediterranean
style” diet are also reported to increase butyrate and, in theory, may
reduce the risk of several diseases linked to aging and the immune
system (43). As we can conclude from the clustering data, several
groups of individuals with different combinations of SCFA
distribution, depressive, and or GI symptoms exist. Whether
symptoms in these groups respond to dietary or supplement-based
interventions in a uniform or differential manner remains to be
seen. Some indications of highly individual reactions to dietary
interventions are emerging (44).
The present study has some limitations. The sample is small,
and individuals with psychiatric morbidity are overrepresented.
The management of samples during collection may have varied
between individuals; however, our previous data show that the
use of SCFA ratios instead of absolute values reduced the influ-
ence of time and temperature on the results (31). Furthermore,
dietary intake is also an important contributor to SCFA levels,
and we do not have information on dietary pattern. An
assessment of systemic SCFA concentrations was not conducted
and would be interesting for future studies. A strength of the
study is the use of dimensional measures of depressive and GI
symptoms, and we have a full range of depressive symptoms
represented in the cohort of young adults. The recruitment base
was an ambulatory care unit within general psychiatry in a
university town; most patients were therefore students, as were
the controls. Patients with severe autism spectra disorders, severe
eating disorders, or psychosis are not represented because they
are generally referred to other units.
This study demonstrates clear interactions between psychiatric
and GI symptoms with SCFA composition in young adults with
primarily affective and/or anxiety disorders and controls without
a psychiatric diagnosis. Biological heterogeneity exists within psy-
chiatric diagnostic groups; this study provides insight into the po-
tential beneficial effects after dietary interventions among potential
subgroups with high acetate and low butyrate and propionate ra-
tios, which should be further explored.
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